NAD+ and precursors dosage: reported doses and schedule
NAD+ helps cells use energy; wellness injection benefits remain unproven.
Also called: NAD+, NAD, nicotinamide adenine dinucleotide, coenzyme I, DPN, NR, nicotinamide riboside, NMN, β-NMN, nicotinamide mononucleotide.
NAD+ and precursors · NAD+ coenzyme and vitamin B3-derived precursors.
Typical reported dose: 25 mg three times a week, building up to 100 mg
- NR: 500 mg: NR 500 mg twice daily. twice daily, by mouth. Studied in a trial. Studied in: Adults with early Parkinson disease. (source)
- NAD+: 750 mg: NAD+ 750 mg once over 6 hours. 750 mg total in saline over 6 hours. once over 6 hours, into a vein. Studied in a trial. Studied in: Healthy men aged 30–55. (source)
- NAD+: 750 mg: NAD+ 750 mg once over 6 hours. once over 6 hours, into a vein. Clinician-published. Studied in: Healthy men aged 30–55. (source)
- NAD+: 10 mg: NAD+ 10 mg IV daily for 7 days, in 100 mL glucose or saline. once daily, into a vein. Studied in a trial. Studied in: Adults with ischemic heart failure; LVEF ≤45%; usual therapy continued. (source)
- NAD+: 5 mg: NAD+ 5 mg once daily during hospitalization. once daily during hospitalization, into muscle. Studied in a trial. Studied in: Adults with sudden sensorineural hearing loss; several standard treatments continued. (source)
- Observed NAD+ IV 500 mg course: NAD+ 500 mg once daily. once daily, into a vein. Clinician-published. Studied in: 14 adults attending a commercial wellness service. (source)
Highest studied: One 14-person crossover trial tested a single 250 mg sublingual NMN tablet..
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to NAD+ and precursors
- MOTS-c: A peptide the body makes; injection benefits and safety remain unproven.
- SS-31 (elamipretide): A peptide approved for Barth syndrome muscle strength; benefit needs confirmation and broader energy benefits remain unproven.
Sources
- GenoGenix LLC - 718739 - 01/20/2026, FDA · FDA · 2026
- Safety of beta-nicotinamide mononucleotide (β-NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC., Turck et al. · EFSA journal. European Food Safety Authority · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- 503A Categories Update for September 2024, FDA · FDA · 2025
- DailyMed - NALTREXONE HYDROCHLORIDE tablet, film coated, DailyMed · 2023
- Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC., Turck et al. · EFSA journal. European Food Safety Authority · 2019
- FDA reminds compounders to use ingredients suitable for sterile compounding, FDA
- FDA to Compounders: Know Your Bulks and Excipients Suppliers, FDA
- Item: /regulated-product-applications/id/application/RP-2116, Food Standards Agency
- Nicotinamide riboside chloride, Food Standards Agency
- NMN 500 (531006), Therapeutic Goods Administration
- Product information, Health Canada
- Re: Docket Number FDA-2023-P-0872, FDA
- Submitted 75-Day Premarket Notifications for New Dietary Ingredients, FDA
- TUE Physician Guidelines: Intravenous infusions and/or injections, World Anti-Doping Agency
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.